Clinical Trial Update: Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating afatinib and selumetinib in advanced KRAS mutant and PIK3CA wildtype non-small cell lung cancer is ongoing, with unknown c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Selumetinib (selumetinib)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN